Our top pick for
US stocks
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
CytoDyn (CYDY) is a biotech firm developing antibodies to combat serious medical conditions, such as HIV and cancer. The company is focused on exploring whether the antibody drug Leronlimab can contribute to the development of an HIV cure. CytoDyn was incorporated in 2002 and is based in Vancouver, Washington USA.
How to buy shares in CytoDyn
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for CytoDyn. Find the share by name or ticker symbol: CYDY. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CytoDyn reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$0.44, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of CytoDyn, depending on your broker.
- Check in on your investment. Congratulations, you own a part of CytoDyn. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Our top pick for
Long-term investing
Our top pick for
Low-cost broker
CytoDyn stock price (OTCQB:CYDY)
Use our graph to track the performance of CYDY stocks over time.CytoDyn shares at a glance
Information last updated 2022-06-27.
| 52-week range | US$0.23 - US$2.54 |
|---|---|
| 50-day moving average | US$0.3478 |
| 200-day moving average | US$0.8324 |
| Target price | US$4 |
| PE ratio | N/A |
| Dividend yield | US$0 (0%) |
| Earnings per share (TTM) | US$-0.225 |
Compare trading apps to buy CytoDyn shares
1 - 7 of 7
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Is it a good time to buy CytoDyn stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
CytoDyn price performance over time
Historical closes compared with the last close of $0.44
| 1 week (2022-06-21) | 22.22% |
|---|---|
| 1 month (2022-05-27) | 29.41% |
| 3 months (2022-03-28) | -4.35% |
| 6 months (2021-12-28) | -56.00% |
| 1 year (2021-06-28) | -74.86% |
|---|---|
| 2 years (2020-06-26) | -93.65% |
| 3 years (2019-06-28) | -5.38% |
| 5 years (2017-06-28) | -43.59% |
CytoDyn financials
| Revenue TTM | US$266,000 |
|---|---|
| Gross profit TTM | US$0 |
| Return on assets TTM | -54.15% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | 0.005 |
| Market capitalisation | US$316.1 million |
TTM: trailing 12 months
CytoDyn share dividends
We're not expecting CytoDyn to pay a dividend over the next 12 months.
CytoDyn share price volatility
Over the last 12 months, CytoDyn's shares have ranged in value from as little as US$0.23 up to US$2.54. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while CytoDyn's is -0.5985. This would suggest that CytoDyn's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, CytoDyn has bucked the trend.
CytoDyn overview
CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). The company has completed a Phase 2b pivotal trial using leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 2b/3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
CytoDyn in the news
Frequently asked questions
More guides on Finder
-
How to buy Kincora Copper (KCC) shares
Steps to owning and managing Kincora Copper shares.
-
How to buy Arcadia Minerals (AM7) shares
Steps to owning and managing Arcadia Minerals shares.
-
How to buy Nexgen Energy (NXG) shares
Steps to owning and managing Nexgen Energy shares.
-
How to buy Keypath Education (KED) shares
Steps to owning and managing Keypath Education shares.
-
What are green bonds and how do they impact the world?
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
-
5 best ways to invest money in Australia in 2022
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
-
How to buy EBR Systems (EBR) shares
Steps to owning and managing EBR Systems shares.
-
How to buy 5E Advanced Materials (5EA) shares
Steps to owning and managing 5E Advanced Materials shares.
-
How to buy Leo lithium shares
Steps to owning and managing Leo lithium shares.
-
How to buy Besra Gold (BEZ) shares
Steps to owning and managing Besra Gold shares.
Ask an Expert
